Andersen G O, Enger M, Skomedal T, Osnes J B
Department of Pharmacology, University of Oslo, Blindern, Norway.
Res Commun Mol Pathol Pharmacol. 1997 Jun;96(3):329-40.
Involvement of receptor subtypes in the alpha 1-adrenoceptor mediated activation of Na/K/2Cl-cotransport and K+ channels was studied in isolated perfused spontaneously beating rat hearts stimulated by phenylephrine (30 mumol/l) in the presence of a beta-adrenoceptor antagonist (1 mumol/l timolol). The effects of alpha 1-adrenoceptor stimulation on K+ translocation mechanisms were studied by measuring the efflux of 86Rb+ (a potassium analogue). The effects of 50 mumol/l bumetanide (Na/K/2Cl-cotransport inhibitor) and 0.1-0.3 mmol/l 4-aminopyridine (inhibitor of K+ channels) were studied in the presence of alpha 1-adrenoceptor subtype selective antagonists. Bumetanide reduced the alpha 1-adrenoceptor mediated increase in 86Rb+ efflux by 53 +/- 16.4% (n = 14, P < 0.001) in hearts pretreated with the preferentially alpha 1B-adrenoceptor antagonist chloroethylclonidine (CEC, 10 mumol/l), and by 35 +/- 7.3% (n = 15, P < 0.001) in the presence of the preferentially alpha 1D-adrenoceptor antagonist BMY 7378 (1 mumol/l). In the presence of the preferentially alpha 1A-adrenoceptor antagonist 5-methylurapidil (10 mumol/l), however, bumetanide had no effect on the response to phenylephrine. 4-Aminopyridine reduced the phenylephrine stimulated 86Rb+ efflux in the presence of 5-methylurapidil, but the effect of the K(+)-channel blocker was eliminated in CEC treated hearts. Thus the effects of the two translocation inhibitors were influenced differently by the two subtype selective antagonists, showing that alpha 1-adrenoceptor stimulation activates a bumetanide sensitive Na/K/2Cl-cotransport mechanism in the rat heart mainly through the alpha 1A-receptor subtype while the 4-aminopyridine sensitive K+ channels, are mainly activated by the alpha 1B-adrenoceptor subtype.
在存在β - 肾上腺素能受体拮抗剂(1μmol / l噻吗洛尔)的情况下,用去氧肾上腺素(30μmol / l)刺激离体灌注的自发搏动大鼠心脏,研究α1 - 肾上腺素能受体介导的钠/钾/ 2氯协同转运体和钾通道激活中受体亚型的参与情况。通过测量86Rb +(钾类似物)的流出量来研究α1 - 肾上腺素能受体刺激对钾转运机制的影响。在存在α1 - 肾上腺素能受体亚型选择性拮抗剂的情况下,研究了50μmol / l布美他尼(钠/钾/ 2氯协同转运体抑制剂)和0.1 - 0.3 mmol / l 4 - 氨基吡啶(钾通道抑制剂)的作用。在用优先作用于α1B - 肾上腺素能受体的拮抗剂氯乙可乐定(CEC,10μmol / l)预处理的心脏中,布美他尼使α1 - 肾上腺素能受体介导的86Rb +流出增加减少了53±16.4%(n = 14,P < 0.001),在存在优先作用于α1D - 肾上腺素能受体的拮抗剂BMY 7378(1μmol / l)的情况下减少了35±7.3%(n = 15,P < 0.001)。然而,在存在优先作用于α1A - 肾上腺素能受体的拮抗剂5 - 甲基尿嘧啶(10μmol / l)的情况下,布美他尼对去氧肾上腺素的反应没有影响。在存在5 - 甲基尿嘧啶的情况下,4 - 氨基吡啶减少了去氧肾上腺素刺激的86Rb +流出,但在CEC处理的心脏中,钾通道阻滞剂的作用被消除。因此,两种转运抑制剂的作用受到两种亚型选择性拮抗剂的不同影响,表明α1 - 肾上腺素能受体刺激在大鼠心脏中主要通过αIA - 受体亚型激活布美他尼敏感的钠/钾/ 2氯协同转运机制,而4 - 氨基吡啶敏感的钾通道主要由α1B - 肾上腺素能受体亚型激活。